content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                   -----------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
              Date of report (Date of earliest event reported): May 4, 2004
                                                                -----------
  
                                CYTOGEN CORPORATION
                -----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------    ------------------------    --------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------   --------------------
           (Address of Principal Executive Offices)                (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  <PAGE>
  
  
  ITEM 12.  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
  
           On May 4, 2004, Cytogen Corporation announced its financial results for
  the quarter  ended  March 31,  2004,  and  reaffirmed  its  previously  provided
  financial  guidance  for 2004.  The full text of the May 4, 2004  press  release
  issued in connection  with the  announcement is attached as Exhibit 99.1 to this
  Current Report on Form 8-K.
  
           The information in this Form 8-K and the exhibit  attached hereto shall
  not be deemed "filed" for purposes of Section 18 of the Securities  Exchange Act
  of 1934 (the  "Exchange  Act") or otherwise  subject to the  liabilities of that
  section,  nor shall it be deemed  incorporated  by reference in any filing under
  the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
  specific reference in such a filing.
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                   CYTOGEN CORPORATION
  
  
  
                                   By:  /s/ Michael D. Becker
                                        --------------------------------------
                                        Michael D. Becker
                                        President and Chief Executive Officer
  
  Dated:  May 4, 2004
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
                    Exhibit No.      Description
                    -----------      -----------
  
                       99.1          Press release dated May 4, 2004
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_050404.txt", "description": "FORM 8-K DATED MAY 4, 2004", "secsgml_size_bytes": 3288}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "04775360"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                   -----------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
              Date of report (Date of earliest event reported): May 4, 2004
                                                                -----------
  
                                CYTOGEN CORPORATION
                -----------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ----------------------------    ------------------------    --------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------   --------------------
           (Address of Principal Executive Offices)                (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  ITEM 12.  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
  
           On May 4, 2004, Cytogen Corporation announced its financial results for
  the quarter  ended  March 31,  2004,  and  reaffirmed  its  previously  provided
  financial  guidance  for 2004.  The full text of the May 4, 2004  press  release
  issued in connection  with the  announcement is attached as Exhibit 99.1 to this
  Current Report on Form 8-K.
  
           The information in this Form 8-K and the exhibit  attached hereto shall
  not be deemed "filed" for purposes of Section 18 of the Securities  Exchange Act
  of 1934 (the  "Exchange  Act") or otherwise  subject to the  liabilities of that
  section,  nor shall it be deemed  incorporated  by reference in any filing under
  the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
  specific reference in such a filing.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                   CYTOGEN CORPORATION
  
                                   By:  /s/ Michael D. Becker
                                        --------------------------------------
                                        Michael D. Becker
                                        President and Chief Executive Officer
  
  Dated:  May 4, 2004
  EXHIBIT INDEX
  
                    Exhibit No.      Description
                    -----------      -----------
  
                       99.1          Press release dated May 4, 2004